Contact   |   Login
Pharmapex’s departments include Animal Health, Human Pharmaceuticals, Human Nutrition, Biotechnology, Consumer Healthcare, and Medical Device and Consumables

Products

At Pharmapex Group, we have a leading portfolio of products that support wellness and prevention, as well as treatment and cures for health-related issues across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared health problems of our time.†

Products by Pharmapex Group are manufactured and handled by its companies mainly in six sectors, namely: Animal Health, Human Pharmaceuticals, Human Nutrition, Biotechnology, Consumer Healthcare, and Medical Device and Consumables. Our group is also actively involved in agribusiness and supports certain subsectors within the food and feed industries by manufacturing products through General Foods North America, its wholly owned food and feed company.

We manufacture many of our products under distinct brand names for sales and distribution in different parts of the world. This assignment of brand names to different territories and our strategic brand management are carried out based on various factors including our corporate policies, global and regional marketing strategies, distributorship arrangements, and product customization. For information about availability of specific brands in your country you may contact our Marketing Department at marketing@pharmapexgroup.com.

Pharmapex continues to raise the bar for product quality and consumer satisfaction. Our commitment to excellence resonates with our client base, which includes a diverse array of corporates, institutions and organizations from around the world.

Major Clientele Groups:

For more information regarding distribution rights, sub-distribution rights, retail opportunities, as well as countrywide representations, please contact our Customer Support Department. We look forward to hearing from you.



† Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specific countries.

You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence.


Quick Contact

Selected Newsletters:

Press Releases and Selected News:
Deferoxamine Mesylate Market to Witness Robust Expansion by 2029 with Teva api, Chengdu Easton Biopharmaceuticals, Pharmapex Group
The Deferoxamine Mesylate Report is a unique record that gives a total judgment of the market in terms of future patterns, development factors, creation volume, CAGR estimation, net revenue, cost, and industry-approved market data.

Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.

FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© , Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.